NORDNordicus Partners Corp.

About Nordicus Partners Corp. (NORD)

Nordicus Partners Corp. (NORD) is a Consulting Services company headquartered in Beverly Hills, CA, United States whose shares trade over-the-counter on the OTCQB tier.

Nordicus Partners Corporation specializes in providing Nordic and U.S. life sciences companies with the best possible conditions to establish themselves on the U.S. market, taking advantage of management's combined +90 years of experience in the corporate sector, serving in different capacities both domestically and globally. Nordicus' core competencies lie in assisting Danish as well as other Nordic and U.S. companies in different areas of corporate finance activities, such as: business- and market development, growth strategies, attracting the right people, partners and capital for businesses and company acquisitions and sales. In May 2024 Nordicus bought 95% of the Danish company, Orocidin A/S, a preclinical-stage biotech company which is advancing the next generation of periodontitis therapies. In November 2024 Nordicus bought 100% of the Danish company, Bio-Convert A/S, a preclinical-stage biotech company focused on revolutionizing the treatment of oral leukoplakia and also in November Nordicus bought the remaining 5% of Orocidin A/S.

Products and services

Nordicus Partners Corporation specializes in providing Nordic and U.S. life sciences companies with the best possible conditions to establish themselves on the U.S. market, taking advantage of management’s combined +90 years of experience in the corporate sector, serving in different capacities both domestically and globally. Nordicus’ core competencies lie in assisting Danish as well as other Nordic and U.S. companies in different areas of corporate finance activities, such as: business- and market development, growth strategies, attracting the right people, partners and capital for businesses and company acquisitions and sales. In May 2024 Nordicus bought 95% of the Danish company, Orocidin A/S, a preclinical-stage biotech company which is advancing the next generation of periodontitis therapies. In November 2024 Nordicus bought 100% of the Danish company, Bio-Convert A/S, a preclinical-stage biotech company focused on revolutionizing the treatment of oral leukoplakia and also in November Nordicus bought the remaining 5% of Orocidin A/S.

NORD key facts

Ticker symbol

NORD

Market tier

OTCQB

Sector

Industrials

Industry

Consulting Services

Headquarters

Beverly Hills, CA, United States

Country of incorporation

US

Year of incorporation

1996

Employees

2

Estimated market cap

$86.42M (as of May 6, 2025)

Shares outstanding

17,283,538

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

3/31

Nordicus Partners Corp. leadership

• Henrik Rouf — CEO
• Bennett J Yankowitz — CFO

Explore more: Consulting Services stocks · Industrials sector · OTCQB stocks · OTC stocks starting with N